Vertex Under Pressure To Spend On M&A
Company Has $6.7bn In Cash
The biotech is growing fast thanks to its success in cystic fibrosis, but is under pressure to be bolder in its business development
You may also be interested in...
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.